Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;7 Suppl 3(Suppl 3):18-23.
doi: 10.1111/irv.12176.

Detection and management of antiviral resistance for influenza viruses

Guy Boivin  1
Affiliations
Review

Detection and management of antiviral resistance for influenza viruses

Guy Boivin. Influenza Other Respir Viruses. 2013 Nov.

Abstract

Neuraminidase inhibitors (NAIs) are first-line agents for the treatment and prevention of influenza virus infections. As for other antivirals, the development of resistance to NAIs has become an important concern particularly in the case of A(H1N1) viruses and oseltamivir. The most frequently reported change conferring oseltamivir resistance in that viral context is the H275Y neuraminidase mutation (N1 numbering). Recent studies have shown that, in the presence of the appropriate permissive mutations, the H275Y variant can retain virulence and transmissibility in some viral backgrounds. Most oseltamivir-resistant influenza A virus infections can be managed with the use of inhaled or intravenous zanamivir, another NAI. New NAI compounds and non-neuraminidase agents as well as combination therapies are currently in clinical evaluation for the treatment for severe influenza infections.

Keywords: Antiviral; influenza; neuraminidase inhibitor; oseltamivir; resistance; zanamivir.

PubMed Disclaimer

Conflict of interest statement

Dr Guy Boivin has received research grants from Roche, GlaxoSmithKline and Biota on the topic of influenza treatment.

Figures

Figure 1
Figure 1
Proposed algorithm for the management of oseltamivir‐resistant influenza virus infections.
See this image and copyright information in PMC

References

    1. Mendel DB, Roberts NA. In‐vitro and in‐vivo efficacy of influenza neuraminidase inhibitors. Curr Opin Infect Dis 1998; 11:727–732. - PubMed
    1. Shiraishi K, Mitamura K, Sakai‐Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine‐treated children with influenza. J Infect Dis 2003; 188:57–61. - PubMed
    1. Ives JA, Carr JA, Mendel DB et al The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307–317. - PubMed
    1. Dharan NJ, Gubareva LV, Meyer JJ et al Infections with oseltamivir‐resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1034–1041. - PubMed
    1. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328:1272–1275. - PMC - PubMed

Publication types

MeSH terms